Sale of Minority Share in Scienta Omicron

Source: RNS
RNS Number : 2202B
Oxford Instruments PLC
29 January 2020
 

 

 

 

Oxford Instruments plc

Sale of Minority Share in Scienta Omicron

 

Oxford, 29 January 2020

 

Oxford Instruments plc, a leading provider of high technology products and services to industrial companies and scientific research communities, today announces that it has completed the sale of its 47% share in Scienta Omicron to a group of existing shareholders in the joint venture for a consideration of SEK 147 million (£11.7 million).

 

The joint venture was established in 2015 consisting of Oxford Instruments' Omicron Nanotechnology GmBH and GDI's Scienta Scientific, creating a leading company in Ultra High Vacuum Surface Science.

 

Ian Barkshire, Chief Executive of Oxford Instruments said, "The sale of our share in Scienta Omicron supports our continued customer-centric focus on our chosen markets with long-term growth drivers where we can maintain or develop leading positions, enhancing our ability to deliver further growth and margin improvement."  

 

 

 

-END-

  

Enquiries:

 

Oxford Instruments plc                                                          Tel:  01865 393200

Ian Barkshire, Chief Executive

Gavin Hill, Group Finance Director

 

MHP Communications                                                           Tel:  020 3128 8100

Rachel Hirst/Alice McLaren

 

 

 

- Ends -

Issued for and on behalf of Oxford Instruments plc

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for 60 years, supporting its core purpose to address some of the world's most pressing challenges. 

 

The first technology business to be spun out from Oxford University, Oxford Instruments is now a global company and is listed on the London Stock Exchange (OXIG).  Its strategy focuses on being a customer-centric, market-focused Group, understanding the technical and commercial challenges faced by its customers. Key market segments include Semiconductor & Communications, Advanced Materials, Healthcare & Life Science, and Quantum Technology.

 

Their portfolio includes a range of core technologies in areas such as low temperature and high magnetic field environments; Nuclear Magnetic Resonance; X-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; and advanced growth, deposition and etching.

 

Oxford Instruments is helping enable a greener economy, increased connectivity, improved health and leaps in scientific understanding. Their advanced products and services allow the world's leading industrial companies and scientific research communities to image, analyse and manipulate materials down to the atomic and molecular level, helping to accelerate R&D, increase manufacturing productivity and make ground breaking discoveries.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISEANFPAEDEEFA